SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Aug 15 3:35 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (1191)4/23/1998 4:12:00 PM
From: Grainne  Read Replies (1) of 1359
 
The information that you provided is really helpful to me, Neuro. It seems very unfair, in a way, that the results reflect trial design failure, not drug failure, and that the results of the studies involving 800 patients are no longer significant because of the failure of this smaller one, but the stock market is not a fair place, and biotech is full of stories like this one.

Do you have any idea of the time frame before we would have results of the new, 700 patient study that Interneuron is laying the groundwork for? Sounds like a long time!! This is all very discouraging, in a way, because Interneuron itself is partially responsible. It makes waiting for drugs in the pipeline look like a pretty rocky ride.

Thanks so much!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News